Inventor

ANDERSEN HENRIK SUNE

DK58 patents

⚠️ This page may combine multiple inventors who share the name “ANDERSEN HENRIK SUNE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ANDERSEN HENRIK SUNE

NOVO NORDISK AS

Modulators of protein tyrosine phosphatases (PTPASES)

Modulators of molecules with phosphotyrosine recognition units

Modulators of molecules with phosphotyrosine recognition units

Modulators of protein tyrosine phosphatases (PTPases)

N-substituted azaheterocyclic carboxylic acids and esters thereof

Modulators of molecules with phosphotyrosine recognition units

Modulators of molecules with phosphotyrosine recognition units

N-substituted azaheterocyclic compounds

N-substituted azaheterocyclic carboxylic acids and esters thereof

Modulators of Protein Tyrosine Phosphatases (PTPases)

Modulators of protein tyrosine phosphatases (PTPases)

Substituted dibenz[b,f]azepines and uses thereof

Pharmaceutical use of fused 1,2,4-triazoles

Somatostatin agonists and antagonists

Modulators of protein tyrosine phosphatases (PTPases)

Modulators of protein tyrosine phosphateses (PTPases)

Heterocyclic compounds

Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)

N-substituted azaheterocyclic carboxylic acids and esters thereof

N-substituted azaheterocyclic carboxlic acids and esters thereof

N-substituted azaheterocyclic carboxylic acids and esters thereof

N-substituted azaheterocyclic carboxylic acids and esters thereof

Modulators of protein tyrosine phosphatases (PTPases)

N-substituted azaheterocyclic carboxylic acids and esters thereof

Modulators of molecules with phosphotyrosine recognition units

N-substituted azaheterocyclic carboxylic acids and esters

Heterocyclic compounds

Heterocyclic compounds

Heterocyclic compounds

Tricyclic compounds in treating hyperalgesic conditions and NIDDM

N-substituted azaheterocyclic carboxylic acids and esters thereof

Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48

Method of treating insulin resistance

Heterocyclic compounds

Heterocyclic compounds

HIGH POINT PHARMACEUTICALS LLC

Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

Pharmaceutical use of fused 1,2,4-triazoles

11β-hydroxysteroid dehydrogenase type 1 active compounds

Pharmaceutical use of substituted amides

11β-hydroxysteroid dehydrogenase type 1 active compounds

11β-hydroxysteroid dehydrogenase type 1 active compounds

Pharmaceutical use of substituted amides

11-beta-hydroxysteroid dehydrogenase type 1 active compounds

KILBURN JOHN PAUL

Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors

11β-hydroxysteroid dehydrogenase type 1 active spiro compounds

NOVO NORDISK HEALTHCARE AG

Growth hormones with prolonged in-vivo efficacy

NOVO NORDISK ALS

N-substituted aza-heterocyclic carboxylic acids and esters thereof

JOHANSEN NILS LANGELAND

Growth hormones with prolonged in-vivo efficacy

BEHRENS CARSTEN

Conjugated proteins with prolonged in vivo efficacy

ANDERSEN METTE DAHL

Antagonistic DR3 ligands